Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals Inc.

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Ionis Pharmaceuticals yesterday and set a price target of $82.00. The company’s shar...

Wells Fargo Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals, with a price targe...

Bank of America Securities Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Ionis Pharmaceuticals, with a price target of $65.00. ...

Current Quarter	$-1.34	Next Quarter	$-0.85
Current Year	$-2.33	Next Year	$-3.39
QoQ Growth	+36.6%	YoY Growth	-45.5%
3Y EPS CAGR	-147.7%	Target Price	$84.10
Consensus	Buy	Upside	+4.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IONS	$80.82	+2.12%	1.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IONS	$80.82	+2.1%	1.47M
3
4
5
6

IONS

IONS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ionis Pharmaceuticals Inc. Data in Excel

Get Ionis Pharmaceuticals Inc. Data in Excel